News: Retapamulin - a new treatment of impetigo in children
Retapamulin
offers an alternative treatment of impetigo in children.
Retapamulin
inhibits protein synthesis through an interaction with the ribosome.
The drug is
indicated for use twice daily for a 5-day period and can be used in treatment
of impetigo in patients aged 9 months or older.
Retapamulin
was approved on the basis of effectiveness data from a placebo-controlled study
comparing it with another antibiotic.
Impetigo is
a contagious skin infection that usually produces blisters or sores on the face
and hands. It is one of the most common skin infections among kids. It is
generally caused by one of two bacteria: group A streptococcus or
staphylococcus aureus.
Reference:
Accessed 20th of December 2007 on Medscape.com
|
Nyhetsbrev
